Attainment of low-density lipoprotein cholesterol goals in coronary artery disease (Q42788572)

7 November 2017

title

Attainment of low-density lipoprotein cholesterol goals in coronary artery disease (English)

1 reference

7 November 2017

1 reference

Thomas Delate

5

1 reference

7 November 2017

Clinical Pharmacy Cardiac Risk Service Study Group

7

1 reference

7 November 2017

Amy B. Kauffman

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:21122649

19 November 2024

Kari L. Olson

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:21122649

19 November 2024

Morgan L. Youngblood

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:21122649

19 November 2024

Emily B. Zadvorny

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:21122649

19 November 2024

John A. Merenich

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:21122649

19 November 2024

language of work or name

English

0 references

publication date

16 March 2010

1 reference

full work available at URL

7 November 2017

https://api.elsevier.com/content/article/PII:S1933287410001017?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/J.JACL.2010.03.002

https://api.elsevier.com/content/article/PII:S1933287410001017?httpAccept=text/plain

19 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.JACL.2010.03.002

Journal of Clinical Lipidology

19 November 2024

published in

1 reference

7 November 2017

volume

4

1 reference

7 November 2017

issue

3

1 reference

7 November 2017

page(s)

173-180

1 reference

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

7 November 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1016/J.JACL.2010.03.002

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

19 November 2024

2

1 reference

https://api.crossref.org/works/10.1016/J.JACL.2010.03.002

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

19 November 2024

3

1 reference

https://api.crossref.org/works/10.1016/J.JACL.2010.03.002

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

19 November 2024

4

1 reference

https://api.crossref.org/works/10.1016/J.JACL.2010.03.002

Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels

19 November 2024

5

1 reference

https://api.crossref.org/works/10.1016/J.JACL.2010.03.002

Statin therapy is associated with reduced mortality across all age groups of individuals with significant coronary disease, including very elderly patients

19 November 2024

6

1 reference

https://api.crossref.org/works/10.1016/J.JACL.2010.03.002

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

19 November 2024

7

1 reference

https://api.crossref.org/works/10.1016/J.JACL.2010.03.002

Intensive versus moderate lipid lowering with statins after acute coronary syndromes

19 November 2024

8

1 reference

https://api.crossref.org/works/10.1016/J.JACL.2010.03.002

Intensive lipid lowering with atorvastatin in patients with stable coronary disease

19 November 2024

9

1 reference

https://api.crossref.org/works/10.1016/J.JACL.2010.03.002

Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial

19 November 2024

10

1 reference

https://api.crossref.org/works/10.1016/J.JACL.2010.03.002

Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial

19 November 2024

11

1 reference

https://api.crossref.org/works/10.1016/J.JACL.2010.03.002

Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the alliance study

19 November 2024

12

1 reference

https://api.crossref.org/works/10.1016/J.JACL.2010.03.002

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

19 November 2024

13

1 reference

https://api.crossref.org/works/10.1016/J.JACL.2010.03.002

Low-density lipoprotein cholesterol goal attainment among high-risk patients: Does a combined intervention targeting patients and providers work?

19 November 2024

14

1 reference

https://api.crossref.org/works/10.1016/J.JACL.2010.03.002

Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee

19 November 2024

15

1 reference

https://api.crossref.org/works/10.1016/J.JACL.2010.03.002

The challenge of achieving national cholesterol goals in patients with diabetes

19 November 2024

16

1 reference

https://api.crossref.org/works/10.1016/J.JACL.2010.03.002

Prevalence and extent of dyslipidemia and recommended lipid levels in US adults with and without cardiovascular comorbidities: the National Health and Nutrition Examination Survey 2003-2004.

19 November 2024

17

1 reference

https://api.crossref.org/works/10.1016/J.JACL.2010.03.002

Extent to which accepted serum lipid goals are achieved in a contemporary general medical population with coronary heart disease risk equivalents

19 November 2024

18

1 reference

https://api.crossref.org/works/10.1016/J.JACL.2010.03.002

Implication of the new low-density lipoprotein goals in dyslipidemia management of patients with acute coronary syndrome

19 November 2024

19

1 reference

https://api.crossref.org/works/10.1016/J.JACL.2010.03.002

Contemporary management of dyslipidemia in high-risk patients: targets still not met

19 November 2024

20

1 reference

https://api.crossref.org/works/10.1016/J.JACL.2010.03.002

Analysis of the degree of undertreatment of hyperlipidemia and congestive heart failure secondary to coronary artery disease

19 November 2024

21

1 reference

https://api.crossref.org/works/10.1016/J.JACL.2010.03.002

The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals

19 November 2024

22

1 reference

https://api.crossref.org/works/10.1016/J.JACL.2010.03.002

Implications of cardiac risk and low-density lipoprotein cholesterol distributions in the United States for the diagnosis and treatment of dyslipidemia: data from National Health and Nutrition Examination Survey 1999 to 2002.

19 November 2024

23

1 reference

https://api.crossref.org/works/10.1016/J.JACL.2010.03.002

Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations

19 November 2024

24

1 reference

https://api.crossref.org/works/10.1016/J.JACL.2010.03.002

LDL-C goal attainment among patients newly diagnosed with coronary heart disease or diabetes in a commercial HMO.

19 November 2024

25

1 reference

https://api.crossref.org/works/10.1016/J.JACL.2010.03.002

Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries

19 November 2024

26

1 reference

https://api.crossref.org/works/10.1016/J.JACL.2010.03.002

Lipid management in patients with coronary artery disease by a clinical pharmacy service in a group model health maintenance organization

19 November 2024

27

1 reference

https://api.crossref.org/works/10.1016/J.JACL.2010.03.002

Clinical pharmacy cardiac risk service for managing patients with coronary artery disease in a health maintenance organization

19 November 2024

28

1 reference

https://api.crossref.org/works/10.1016/J.JACL.2010.03.002

Assessment of patient satisfaction with telephone and mail interventions provided by a clinical pharmacy cardiac risk reduction service

19 November 2024

29

1 reference

https://api.crossref.org/works/10.1016/J.JACL.2010.03.002

A chronic disease score from automated pharmacy data

19 November 2024

30

1 reference

https://api.crossref.org/works/10.1016/J.JACL.2010.03.002

Lipid treatment assessment project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals.

19 November 2024

31

1 reference

https://api.crossref.org/works/10.1016/J.JACL.2010.03.002

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre ra

19 November 2024

32

1 reference

https://api.crossref.org/works/10.1016/J.JACL.2010.03.002

Mortality reduction benefits of a comprehensive cardiac care program for patients with occlusive coronary artery disease

19 November 2024

33

1 reference

https://api.crossref.org/works/10.1016/J.JACL.2010.03.002

Correlates of LDL-cholesterol goal attainment in patients under lipid lowering therapy

19 November 2024

34

1 reference

https://api.crossref.org/works/10.1016/J.JACL.2010.03.002

Gender differences in mortality after myocardial infarction. Why women fare worse than men.

19 November 2024

35

1 reference

https://api.crossref.org/works/10.1016/J.JACL.2010.03.002

Opportunity for intervention to achieve American Heart Association guidelines for optimal lipid levels in high-risk women in a managed care setting

19 November 2024

36

1 reference

https://api.crossref.org/works/10.1016/J.JACL.2010.03.002

A comprehensive view of sex-specific issues related to cardiovascular disease

19 November 2024

37

1 reference

https://api.crossref.org/works/10.1016/J.JACL.2010.03.002

Age and sex differences in the treatment of patients with initial acute myocardial infarction: a community-wide perspective

19 November 2024

38

1 reference

https://api.crossref.org/works/10.1016/J.JACL.2010.03.002

Retrospective review of sex differences in the management of dyslipidemia in coronary heart disease: an analysis of patient data from a Maryland-based health maintenance organization

19 November 2024

39

1 reference

https://api.crossref.org/works/10.1016/J.JACL.2010.03.002

Angina and cardiac care: are there gender differences, and if so, why?

19 November 2024

40

1 reference

https://api.crossref.org/works/10.1016/J.JACL.2010.03.002

Prevalence of insulin resistance and associated cardiovascular disease risk factors among normal weight, overweight, and obese individuals

19 November 2024

41

1 reference

https://api.crossref.org/works/10.1016/J.JACL.2010.03.002

Defining outcomes in older patients with cardiovascular disease

19 November 2024

42

1 reference

https://api.crossref.org/works/10.1016/J.JACL.2010.03.002

Acute myocardial infarction in the Medicare population. Process of care and clinical outcomes

19 November 2024

43

1 reference

https://api.crossref.org/works/10.1016/J.JACL.2010.03.002

Factors associated with recurrent coronary events among patients with cardiovascular disease

19 November 2024

44

1 reference

https://api.crossref.org/works/10.1016/J.JACL.2010.03.002

19 November 2024

45

1 reference

https://api.crossref.org/works/10.1016/J.JACL.2010.03.002

19 November 2024

Identifiers

1 reference

7 November 2017

1 reference